

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	("6214813").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:18
S2	578	mc5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/22 14:17
S3	31	S2 and psoriasis	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/22 14:20
S4	106	"integrin-linked kinase"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:27
S5	134	"mc-5"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/22 14:56
S6	2	("6013782").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/22 14:58
S7	2	("6001622").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/22 14:58
S8	2	("6338958").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/25 14:42
S9	546	wortmannin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/26 15:01
S10	214	S9 and inflammation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:16
S11	287	ly294002	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:20
S12	578	mc5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:20

S13	82	S12 and inflammation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:20
S14	106	"integrin-linked kinase"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:27
S15	49	S14 and inflammation	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/25 15:27
S16	547	wortmannin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/26 15:01
S17	104	S16 and psoriasis	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/04/26 15:02
S18	2	("4900727").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:01
S19	2	("4179447").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:01
S20	2	("4841078").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:02
S21	2	("5284856").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:04
S22	2	("3947462").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:05
S23	2	("4853400").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:05
S24	2	("4678787").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:06

S25	2	("4169097").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:06
S26	2	("6291447").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:19
S27	2	("6046224").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/04/26 16:19

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
 AN 2005:170690 CAPLUS
 TI Functional consequences of integrin-linked kinase activation in podocyte damage
 AU Teixeira, Vicente de Paulo Castro; Blattner, Simone Monika; Li, Min; Anders, Hans-Joachim; Cohen, Clemens David; Edenhofer, Ilka; Calvaresi, Novella; Merkle, Monika; Rastaldi, Maria Pia; Kretzler, Matthias
 CS Medizinische Poliklinik, Universitaet Muenchen, Munich, Germany
 SO Kidney International (2005), 67(2), 514-523
 CODEN: KDYIA5; ISSN: 0085-2538
 PB Blackwell Publishing, Inc.
 DT Journal
 LA English

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Background. The delicate foot process architecture of glomerular podocytes critically depends on **integrin** mediated cell-glomerular basement membrane (GBM) interaction. **Integrin** signaling via the **integrin**-linked kinase (ILK) is activated in podocyte damage and associated with considerable podocyte phenotype alterations. ILK has been shown to regulate cell fate via nuclear interaction of β -catenin with lymphoid enhancer factor (LEF-1) transcription factors. The aim of this study was to elucidate the mol. mechanisms of ILK dependant phenotype regulation in podocytes. Methods. ILK function was evaluated in conditionally immortalized murine glomerular epithelial cells using overexpression of ILK and a small mol. ILK inhibitor in puromycin/adriamycin-induced podocyte damage in vitro and in vivo. Results. Kinase active, but not mutant ILK induced translocation of β -catenin to the cell nucleus, de novo expression of LEF-1, and nuclear colocalization of β -catenin and LEF-1. The role of ILK signaling in podocyte damage was evaluated using puromycin, an agent known to cause selective proteinuria and to increase ILK activity. The small mol. ILK inhibitor **MC-5** blocked puromycin-induced nuclear translocation of β -catenin, podocyte detachment, cell proliferation, and repression of the slit membrane mols. β -cadherin and CD2ap. In vivo activation of the β -catenin pathway could be shown by nuclear colocalization of β -catenin with WT-1 in adriamycin nephropathy. Conclusion. ILK regulates podocyte cell matrix interaction, proliferation, and slit membrane gene expression in podocyte damage. As this pathway is amendable to pharmacol. intervention, further detailed studies of in vivo ILK function in glomerular disease appear justified.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
 AN 2002:814680 CAPLUS
 DN 137:304771
 TI Treatment of inflammatory diseases including psoriasis with integrin-linked kinase inhibitors
 IN Dedhar, Shoukat; Hannigan, Greg; Hunt, David W. C.; Tao, Jing-Song; Fazli, Ladan
 PA Can.
 SO U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. 6,338,958.
 CODEN: USXXCO
 DT Patent
 LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002155179	A1	20021024	US 2001-998250	20011130
	US 6013782	A	20000111	US 1997-955841	19971021
	US 6001622	A	19991214	US 1998-35706	19980305
	US 6338958	B1	20020115	US 1999-390425	19990903
PRAI	US 1995-9074P	P	19951221		
	US 1996-752345	B2	19961119		
	US 1997-955841	A2	19971021		
	US 1998-35706	A1	19980305		
	US 1999-390425	A2	19990903		

AB Inhibitors of **integrin**-linked kinase (ILK) are used in the

treatment of inflammatory disease, including cutaneous inflammatory diseases, such as psoriasis, scleroderma, systemic lupus erythematosus and atopic dermatitis. When zymosan was administered to mice, peritoneal cavity neutrophil nos. increased by approx. 4-fold within 4 h. However, if **MC-5** was given orally at 200 mg/kg at the time of zymosan administration cells nos. within the peritoneal cavity were equivalent to those of animals that received a saline control solvent 4 h before. Thus, a compound with specific in vitro anti-ILK activity can affect the influx of cells into a tissue following the delivery of a strong pro-inflammatory signal in vivo.

IT Neutrophil

(**MC-5** inhibition of influx of, into site of inflammation; treatment of inflammatory diseases including psoriasis with **integrin**-linked kinase inhibitors)

IT 472998-84-8, **MC 5** (pharmaceutical)

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of inflammatory diseases including psoriasis with **integrin**-linked kinase inhibitors)

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 472998-84-8 REGISTRY
ED Entered STN: 11 Nov 2002
CN MC 5 (pharmaceutical) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN MC 5
ENTE An integrin-linked kinase inhibitor
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:814680 CAPLUS
 DN 137:304771
 TI Treatment of inflammatory diseases including psoriasis with
 integrin-linked kinase inhibitors
 IN Dedhar, Shoukat; Hannigan, Greg; Hunt, David W. C.; Tao, Jing-Song; Fazli,
 Ladan
 PA Can.
 SO U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. 6,338,958.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002155179	A1	20021024	US 2001-998250	20011130
	US 6013782	A	20000111	US 1997-955841	19971021
	US 6001622	A	19991214	US 1998-35706	19980305
	US 6338958	B1	20020115	US 1999-390425	19990903
PRAI	US 1995-9074P	P	19951221		
	US 1996-752345	B2	19961119		
	US 1997-955841	A2	19971021		
	US 1998-35706	A1	19980305		
	US 1999-390425	A2	19990903		
IT	472998-84-8 , MC 5 (pharmaceutical) RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment of inflammatory diseases including psoriasis with integrin-linked kinase inhibitors)				

L8 ANSWER 2 OF 2 USPATFULL on STN
 AN 2002:279747 USPATFULL
 TI Treatment of inflammatory diseases including psoriasis
 IN Dedhar, Shoukat, Richmond, CANADA
 Hannigan, Greg, Toronto, CANADA
 Hunt, David W.C., Surrey, CANADA
 Tao, Jing-Song, Vancouver, CANADA
 Fazli, Ladan, North Vancouver, CANADA
 PI US 2002155179 A1 20021024
 AI US 2001-998250 A1 20011130 (9)
 RLI Continuation-in-part of Ser. No. US 1999-390425, filed on 3 Sep 1999,
 GRANTED, Pat. No. US 6338958 Continuation of Ser. No. US 1998-35706,
 filed on 5 Mar 1998, GRANTED, Pat. No. US 6001622 Continuation-in-part
 of Ser. No. US 1997-955841, filed on 21 Oct 1997, GRANTED, Pat. No. US
 6013782 Continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov
 1996, ABANDONED
 PRAI US 1995-9074P 19951221 (60)
 DT Utility
 FS APPLICATION
 LREP PAMELA J. SHERWOOD, Bozicevic, Field and Francis LLP, Suite 200, 200
 Middlefield Road, Menlo Park, CA, 94025
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 818
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT **472998-84-8**, MC 5 (pharmaceutical)
 (treatment of inflammatory diseases including psoriasis with
 integrin-linked kinase inhibitors)

=>